Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants.
Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants.
复制标题
DOI：
10.1016/j.medj.2022.04.013
复制
发表时间：
2022-06-10
期刊：
影响因子：
17
通讯作者：
Hamaguchi, Isao
中科院分区：
文献类型：
--
作者：
Seki, Yohei;Yoshihara, Yasuo;Nojima, Kiyoko;Momose, Haruka;Fukushi, Shuetsu;Moriyama, Saya;Wagatsuma, Ayumi;Numata, Narumi;Sasaki, Kyohei;Kuzuoka, Tomoyo;Yato, Yoshiyuki;Takahashi, Yoshimasa;Maeda, Ken;Suzuki, Tadaki;Mizukami, Takuo;Hamaguchi, Isao
2021 年 11 月在日本发现了严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 的 Omicron 变体。该变体在中和抗体的目标刺突蛋白中含有多达 36 个突变，可以逃避疫苗诱导的免疫。医护人员和高危人群开始了加强疫苗接种活动。针对 Omicron 的三剂疫苗接种的安全性和免疫原性仍不清楚。共有 272 名医护人员初步评估了疫苗的长期安全性和免疫原性。我们进一步建立了一个疫苗接种者小组，使用活病毒微中和测定来评估针对关注变体（VOC）（包括 Omicron 变体）的安全性和免疫原性。两剂疫苗接种诱导了针对祖先菌株 WK-521 的强大抗刺突抗体和中和滴度 (NT)，而针对 VOC 的 NT 明显较低。在接种第二剂疫苗后的 93-247 天内，接种组中多达 80% 的个体完全消除了针对 Omicron 的 NT。加强剂量诱导针对 WK-521、Delta 和 Omicron 变体的抗尖峰抗体和 NT 的强劲增加。在 Omicron 亚变体 BA.1、BA.1.1 和 BA.2 中，来自加强个体的血清中和能力没有显着差异。 Boosting 增加了体液免疫的广度和与 Omicron 的交叉反应性，且不改变细胞因子特征和不良事件发生率。第三剂疫苗接种是安全的，并且可以增强对 Omicron 变体的中和作用。这项研究得到了 AMED 的资助（资助 JP21fk0108104 和 JP21mk0102146）。 SARS-CoV-2 Omicron 变体后来被命名为 BA.1，由于其刺突蛋白（中和抗体的目标）有 36 个突变，已成为一种高度传播的变体；因此它可以逃避疫苗诱导的免疫力。 Omicron 亚变体 BA.2 最近被发现，并迅速成为包括日本在内的许多国家关注的主要变体。这项研究发现，第二次疫苗接种后 6-9 个月，抗尖峰抗体水平和中和能力逐渐下降。第三剂显着增强了针对多种 Omicron 变体的反应。这些结果表明，加强注射可增加针对 SARS-CoV-2 变体的中和抗体。关等人。报告称，三剂辉瑞/BioNTech mRNA 疫苗接种后，针对 WK-521、Delta 和 Omicron 变体的抗尖峰抗体和中和滴度大幅增加。针对 Omicron 亚变体（包括 BA.1、BA.1.1 和三个不同的 BA.2 亚变体）的免疫原性在第三剂疫苗接种后没有变化。
The Omicron variant of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) was identified in Japan in November 2021. This variant contains up to 36 mutations in the spike protein, the target of neutralizing antibodies, and can escape vaccine-induced immunity. A booster vaccination campaign began with healthcare workers and high-risk groups. The safety and immunogenicity of the three-dose vaccination against Omicron remain unknown. A total of 272 healthcare workers were initially evaluated for long-term vaccine safety and immunogenicity. We further established a vaccinee panel to evaluate the safety and immunogenicity against variants of concern (VOCs), including the Omicron variants, using a live virus microneutralization assay. Two-dose vaccination induced robust anti-spike antibodies and neutralization titers (NTs) against the ancestral strain WK-521, whereas NTs against VOCs were significantly lower. Within 93–247 days of the second vaccine dose, NTs against Omicron were completely abolished in up to 80% of individuals in the vaccinee panel. Booster dose induced a robust increase in anti-spike antibodies and NTs against the WK-521, Delta, and Omicron variants. There were no significant differences in the neutralization ability of sera from boosted individuals among the Omicron subvariants BA.1, BA.1.1, and BA.2. Boosting increased the breadth of humoral immunity and cross-reactivity with Omicron without changes in cytokine signatures and adverse event rate. The third vaccination dose is safe and increases neutralization against Omicron variants. This study was supported by grants from AMED (grants JP21fk0108104 and JP21mk0102146). The SARS-CoV-2 Omicron variant, later named BA.1, has emerged as a highly transmissible variant due to the 36 mutations in its spike protein, which is the target of neutralizing antibodies; it can therefore escape vaccine-induced immunity. The Omicron subvariant, BA.2, was recently identified and has rapidly become a major variant of concern in many countries, including Japan. This study found that anti-spike antibody levels and neutralization ability decreased gradually 6–9 months after the second vaccination. A third dose dramatically increased the response against multiple Omicron variants. These results show that a booster shot increases neutralization antibodies against SARS-CoV-2 variants. Seki et al. report that a three-dose Pfizer/BioNTech mRNA vaccination induced a robust increase in anti-spike antibodies and neutralization titers against the WK-521, Delta, and Omicron variants. Immunogenicity against Omicron subvariants, including BA.1, BA.1.1, and three different BA.2 subvariants did not change following the third vaccine dose.
登录
查看更多内容
影响因子：
32.4
作者：
Moriyama S;Adachi Y;Sato T;Tonouchi K;Sun L;Fukushi S;Yamada S;Kinoshita H;Nojima K;Kanno T;Tobiume M;Ishijima K;Kuroda Y;Park ES;Onodera T;Matsumura T;Takano T;Terahara K;Isogawa M;Nishiyama A;Kawana-Tachikawa A;Shinkai M;Tachikawa N;Nakamura S;Okai T;Okuma K;Matano T;Fujimoto T;Maeda K;Ohnishi M;Wakita T;Suzuki T;Takahashi Y
通讯作者：
Takahashi Y
影响因子：
64.8
作者：
Barnes CO;Jette CA;Abernathy ME;Dam KA;Esswein SR;Gristick HB;Malyutin AG;Sharaf NG;Huey-Tubman KE;Lee YE;Robbiani DF;Nussenzweig MC;West AP Jr;Bjorkman PJ
通讯作者：
Bjorkman PJ
影响因子：
64.8
作者：
Gaebler C;Wang Z;Lorenzi JCC;Muecksch F;Finkin S;Tokuyama M;Cho A;Jankovic M;Schaefer-Babajew D;Oliveira TY;Cipolla M;Viant C;Barnes CO;Bram Y;Breton G;Hägglöf T;Mendoza P;Hurley A;Turroja M;Gordon K;Millard KG;Ramos V;Schmidt F;Weisblum Y;Jha D;Tankelevich M;Martinez-Delgado G;Yee J;Patel R;Dizon J;Unson-O'Brien C;Shimeliovich I;Robbiani DF;Zhao Z;Gazumyan A;Schwartz RE;Hatziioannou T;Bjorkman PJ;Mehandru S;Bieniasz PD;Caskey M;Nussenzweig MC
通讯作者：
Nussenzweig MC
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
两种抗体鸡尾酒中和中和的遗传和结构基础。
影响因子：
28.3
作者：
Dong J;Zost SJ;Greaney AJ;Starr TN;Dingens AS;Chen EC;Chen RE;Case JB;Sutton RE;Gilchuk P;Rodriguez J;Armstrong E;Gainza C;Nargi RS;Binshtein E;Xie X;Zhang X;Shi PY;Logue J;Weston S;McGrath ME;Frieman MB;Brady T;Tuffy KM;Bright H;Loo YM;McTamney PM;Esser MT;Carnahan RH;Diamond MS;Bloom JD;Crowe JE Jr
通讯作者：
Crowe JE Jr